AZN
ASTRAZENECA PLCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 20 ▼ 1 insider sell $2.2M at $185.78
- Jun 29 to Jul 9 3 court rulings: Factor Bioscience Inc. v. Cellectis, Inc., Cellectis S.A…; AstraZeneca v. Murrill and 1 more
- Jun 30 ▲ 10 funds open new positions (13F)
- Jul 23 to Aug 3 3 court rulings: Dressen v. AstraZeneca AB, et al; ASTRAZENECA PHARMACEUTICALS LP v. FREY et al and 1 more
- Aug 8 ▲ 1 insider buy $3.2K at $160.57
- Aug 24 CICC initiates
- Sep 30 ▼ Short interest jumps 25.4% to 2.62M
- Oct 2 ASTRAZENECA PHARMACEUTICALS LP et al v. SANDOZ INC. et al
- Oct 13 to Oct 15 2 court rulings: Johnson v. ASTRAZENECA PHARMACEUTICALS LP et al; Shareholder Representative Services, LLC v. Alexion…
- Oct 15 ▼ Short interest jumps 25.4% to 3.28M
- Oct 22 ▲ AstraZeneca announced that the FDA granted accelerated approval for…
- Nov 13 ▲ Drug approval: EMA: Human medicines European public assessment report (EP…
- Nov 16 New report: subscribers see the details Unlock
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $3.2K at an average $160.57. 1 insider sold $2.2M. Price is 15% above their cost.
- InstitutionsBULLISH
Q2 2026: 53 added (10 new), 27 trimmed or exited. Largest new: Dimensional Fund Advisors $551.0M, Caisse De Depot Et Placement Du Quebec $273.9M.
- AnalystsBULLISH
28 of 34 rate it Buy or better. Median target $210.00 (+14%).
- Short sellersSTEADY
Short interest −7.7% to 3.03M shares. 1.0 days to cover, ≈0.2% of shares.
- TrendUPTREND
9% above its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 2 mentions: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| NORGES BANK | DOUBLED | $6.3B |
| CAUSEWAY CAPITAL MANAGEMENT LLC | ADD | $1.8B |
| Rathbones Group PLC | DOUBLED | $1.5B |
| CITIGROUP INC | ADD | $916.2M |
| Boston Partners | ADD | $597.4M |
| DIMENSIONAL FUND ADVISORS LP | NEW | $551.0M |
| RAYMOND JAMES FINANCIAL INC | ADD | $456.9M |
| JONES FINANCIAL COMPANIES LLLP | ADD | $314.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
34 analystsPrice is inside the target range. Median implies +14%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 24, 2026 | CICC INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sharma Mani See remarks Nov 6, 2026 | AWARD | $186.24 |
Sharma Mani See remarks Oct 6, 2026 | AWARD | $319.60 |
Sharma Mani See Remarks Sep 8, 2026 | AWARD | $162.60 |
Sharma Mani See Remarks Aug 8, 2026 | BUY | $3.2K |
Sharma Mani SVP, Group Controller Aug 6, 2026 | AWARD | $326.68 |
Sharma Mani See Remarks Jul 6, 2026 | AWARD | $380.86 |
Sharma Mani See Remarks Jun 8, 2026 | AWARD | $179.75 |
Sharma Mani See Remarks May 20, 2026 | SELL | $2.2M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $16.0B |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
77 filings · 38 bullish · 4 bearish · 4 mixed · 31 neutral- BULLISH 6-KNov 16, 2026
AstraZeneca announced that the CHMP of the EMA has recommended approval of Baxfendy (baxdrostat) in the EU for adults with hypertension insufficiently controlled on at least two antihypertensives. If approved, Baxfendy would be the first aldosterone synthase inhibitor in the EU, supported by Phase…
🔒 Fresh report (last 24h), subscribers only
- BULLISH 6-KNov 16, 2026
AstraZeneca announced FDA approval of Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) as neoadjuvant treatment followed by Imfinzi monotherapy as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based…
🔒 Fresh report (last 24h), subscribers only
- BULLISH 6-KNov 16, 2026
AstraZeneca's Alexion unit received FDA approval for Klygefa (gefurulimab), a once-weekly subcutaneous C5 inhibitor for AChR antibody-positive generalized myasthenia gravis. The approval was supported by Phase III PREVAIL trial data showing statistically significant improvement in MG-ADL scores at…
🔒 Fresh report (last 24h), subscribers only
- BULLISH 6-KNov 16, 2026
AstraZeneca's Alexion unit received EU approval for Klygefa (gefurulimab), a first-in-class dual-binding nanobody C5 inhibitor for generalized myasthenia gravis. The approval, based on the Phase III PREVAIL trial showing rapid and sustained disease control, adds a differentiated self-administered…
🔒 Fresh report (last 24h), subscribers only
All AZN filing & press-release reports (77)
- 6-K reportNov 16, 2026
- 6-K reportNov 16, 2026
- 6-K reportNov 16, 2026
- 6-K reportNov 16, 2026
- INST-CLUSTER reportNov 4, 2026
- 6-K reportNov 2, 2026
- 6-K reportNov 2, 2026
- 6-K reportOct 30, 2026
- 6-K reportOct 27, 2026
- 6-K reportOct 22, 2026
- COURT-RULING reportOct 15, 2026
- 6-K reportOct 5, 2026
- 6-K reportOct 2, 2026
- COURT-RULING reportOct 2, 2026
- 6-K reportOct 1, 2026
- 6-K reportOct 1, 2026
- 6-K reportSep 29, 2026
- 6-K reportSep 23, 2026
- 6-K reportSep 21, 2026
- 6-K reportSep 21, 2026
- 6-K reportSep 18, 2026
- COURT-RULING reportSep 17, 2026
- 6-K reportSep 15, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 8, 2026
- COURT-RULING reportAug 31, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportAug 25, 2026
- COURT-RULING reportAug 21, 2026
- COURT-RULING reportAug 18, 2026
- 6-K reportAug 19, 2026
- 6-K reportAug 17, 2026
- 6-K reportAug 17, 2026
- COURT-RULING reportAug 3, 2026
- 6-K reportAug 3, 2026
- COURT-RULING reportJul 27, 2026
- 6-K reportJul 31, 2026
- 6-K reportJul 27, 2026
- 6-K reportJul 27, 2026
- 6-K reportJul 27, 2026
- COURT-RULING reportJul 23, 2026
- 6-K reportJul 14, 2026
- COURT-RULING reportJul 9, 2026
- 6-K reportJul 9, 2026
- COURT-RULING reportJul 6, 2026
- 6-K reportJun 29, 2026
- 6-K reportJul 1, 2026
- 6-K reportJul 1, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 1, 2026
- 6-K reportJun 1, 2026
- 6-K reportMay 29, 2026
- 25-NSE reportMay 28, 2026
- COURT-RULING reportMay 27, 2026
- 6-K reportMay 27, 2026
- 6-K reportMay 26, 2026
- 6-K reportMay 26, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 14, 2026
- 6-K reportMay 1, 2026
- 6-K reportApr 29, 2026
- 6-K reportApr 28, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 21, 2026
- 6-K reportApr 20, 2026
- 25-NSE reportApr 8, 2026
- 6-K reportApr 2, 2026
- 6-K reportMar 31, 2026
- COURT-RULING reportMar 30, 2026
- 6-K reportMar 27, 2026